Archives, Room Use Only - TK5263.C655 1875

Archives, Room Use Only - Q164.J85 1829

Archives, Room Use Only - TK9946.D87 1923

Archives, Room Use Only - QC544.G2 H37 1890

Archives, Room Use Only - TK5102.5.B96 1934

Archives, Room Use Only - UG575.G7 G74 1915

Archives, Room Use Only - VK381.B76 1917

Archives, Room Use Only - V850.G74 1911

Archives, Room Use Only - TK5264.M36 1894

From PPEs to ventilators to face shields, manufacturers have invested money to ramp up production and deliver during this crisis

Bihar chief minister Nitish Kumar on Saturday asked state’s chief secretary Deepak Kumar to take necessary steps to create employment opportunities for returning migrant workers as per the outcome of their skill survey.

A historical tool for crystallographic analysis is provided by the Hilton net, which can be used for manually surveying the crystal lattice as it is manifested by the Kikuchi bands in a gnomonic projection. For a quantitative analysis using the Hilton net, the projection centre as the relative position of the signal source with respect to the detector plane needs to be known. Interplanar angles are accessible with a precision and accuracy which is estimated to be ≤0.3°. Angles between any directions, e.g. zone axes, are directly readable. Finally, for the rare case of an unknown projection-centre position, its determination is demonstrated by adapting an old approach developed for photogrammetric applications. It requires the indexing of four zone axes [uvw]i in a backscattered Kikuchi diffraction pattern of a known phase collected under comparable geometric conditions.

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Tom Rachal (R) receives a free meningitis vaccine from Dr. Wayne Chen at the AIDS Healthcare Foundation pharmacy on April 15, 2013 in Hollywood, California. Los Angeles County's unemployment rate is 7.9%, down from 9.2% a year ago, and once again it was healthcare that added the most jobs: 22,000.
; Credit: Kevork Djansezian/Getty Images

If you want a job in Los Angeles County, you’re best off being a nurse or a hotel worker and you’re less likely to find employment in manufacturing. 

We’re getting our first look at the employment numbers for 2014, which show mostly good news: California’s unemployment has fallen to 7 percent, the lowest rate in five and a half years. (The final numbers come out in March)

The state’s job growth outpaced the rest of the country for the third straight year, though it slowed slightly towards the end of the year.

California added jobs at a 2.2 percent annual rate last year, outpacing the nation’s 1.8 percent rate. 

Los Angeles County fared the worst as far as seasonally adjusted year-to-year job gains among California's major metropolitan areas, according to The Los Angeles County Economic Development Corp.:

• San Jose/Silicon Valley +4 percent
• San Francisco Bay Area + 3.8 percent 
• San Diego +3.3 percent
• Inland Empire +1.9 percent
• Orange County +2.3 percent
• Ventura +2 percent
• Los Angeles +1.7 percent

Los Angeles County's unemployment rate is 7.9 percent, down from 9.2 percent a year ago, and once again it was health care that added the most jobs: 22,000.

"Part of it is demographic, and part of it was the Affordable Care Act, which is helping more individuals take advantage of health care," said Robert Kleinhenz, Chief Economist at the L.A. County Economic Development Corp.

Aside from an aging population needing more health care, Kleinhenz adds that more people can afford to get medical treatment because of the improvement in the economy. 

With more money in their pockets, more people have also been traveling, which made leisure and hospitality the second-best area for job growth in the county, with 11,300 new jobs.

What's not doing well? 

Manufacturing, especially in non-durable goods – which includes food and clothing – lost the most jobs in L.A. County in 2014: 6,700 jobs. The only other sector that shed jobs was the government, which lost almost 3,800 jobs positions last year.

Kleinhenz also pointed to wholesale trade, which lost 300 jobs year-to-year in but saw job growth in the Inland Empire. 

"Some parts of the goods movement may be moving into the Inland Empire, where we have seen in recent years quite a bit of warehouse building taking place,” said Kleinhenz. 

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Asia Credit Card Production (ACC) has selected 

Organisations are increasingly applying green business principles. According to a recent study, electronics manufacturing companies in Taiwan that practice green supply chain management (GSCM) have a better business performance than companies that do not. Those with a strong green marketing focus performed the best, successfully competing with their rivals.

International rail vehicle construction company, Stadler, disclosed that it was the victim of a cyberattack which might have also allowed the attackers to steal company and employee data. [...]

Researchers from the University of Oxford's Bodleian Libraries and from universities in the Netherlands have used high-tech imaging to uncover the details of a rare Mexican codex dating from before the colonization of the Americas. The newly revealed codex, or book, has been hidden from view for almost 500 years, concealed beneath a layer of plaster and chalk on the back of a later manuscript known as the Codex Selden, which is housed at the Bodleian Libraries. Scientists have used hyperspectral imaging to reveal pictographic scenes from this remarkable document and have published their findings in the Journal of Archaeological Science: Reports.

read more

The pressures facing Indian manufacturers to ‘green’ their supply chain have been explored by a recent study. Both international and national pressures from government and consumers were found to play an important role in whether a company adopts green supply chain management principles, with pressures varying to some degree depending on the business’s sector and size.

Consumers in France, Germany and the USA perceive ‘environmentally friendly’ packaging to be reusable, recyclable and ‘biodegradable’1, finds a new study. These results suggest that producers should emphasise the end-of-life merits of packaging to appeal to consumers’ environmental concerns, and design packaging that is reusable, recyclable and ‘biodegradable’. However, they also indicate a need to raise public awareness of packaging’s true life-cycle environmental impacts, such as those during production and transport, which are greater than consumers generally perceive them to be.

‘Perovskite solar cells’ (PSCs) are less costly than conventional silicon solar cells, but one of their key components is energy-intensive to manufacture as high temperatures are needed. Now researchers have identified new alternative materials for this component which cut energy demands as they can be produced at low temperatures.

Shortages of indium, a key metal found in thin-film solar cells, could limit their large-scale deployment in the future. A new study has outlined four ways that indium supplies could be increased to meet future demand. For example, indium could be extracted more efficiently from zinc ores, or historic wastes containing indium could be processed to extract the element.

An inventory of materials used in ship construction could minimise waste and increase ships’ recycling rates and resale value, according to the Sustainable Shipping Initiative (SSI). Although extra data management would be required on the part of suppliers, manufacturers and owners, it would help make the industry more efficient and future-proof with regard to developments in international legislation on ship building.

Phosphorus in sewage and manure could be more available to crops than previously thought, suggests new research. The study found that some forms of sewage and manure treatment provided plants with more phosphorus than conventional inorganic fertilisers.

Sixty-six per cent of manufacturing companies voted for big data, predictive analytics as their top investment priority in the next two years, followed by the Industrial Internet of Things (IIoT) and sensors, cloud/integrated platforms and robotic process automation, a new study revealed on Friday.

Xiaomi's arch rival, Madhav Sheth-led Realme, has revealed plans to become a tech-lifestyle company in India next year, with introducing a bouquet of IoT products. Others are following suit too. Xiaomi has already shared how its AIoT (AI+IoT) dual strategy is going to shape its product vision.

Maitrey Modha of CNH Industrial says IoT companies would need to come up with customized solutions based on each type of manufacturing process.

A recent Bulgarian study has proposed a more environmentally friendly approach to manufacturing chemicals and biochemicals in multipurpose batch plants, which carefully considers how the production process is scheduled.

Nanolithography — a way of making finely detailed patterns or structures, such as those found in advanced computer microchips, uses toxic and corrosive chemicals. Researchers have now shown that these could be replaced with eco-friendly silk proteins and water, eliminating the need to use and dispose of hazardous chemicals, while achieving similar levels of detail to conventional methods.

Vermicomposting livestock manure with maize can increase agricultural benefit by 304%, shows a new study. The combination of increased crop yield and the additional earthworms produced as a result of the process led to a substantial increase in output compared to a traditional composting system.

A new study has investigated the movement of antibiotic resistance genes between farm animals, soil and water in Finland. The results show that many of these genes are spread from animals to the soil through manure application; however, these genes do not appear to persist in soil. The study suggests that practices that minimise the use of antibiotics, as used in Finland, may lead to lower levels of clinically relevant resistance genes in agricultural soils.

Engineering at the nanoscale brings the promise of radical technological development — clean energy, highly effective medicines and space travel. But technology at this scale also brings safety challenges. Nano-sized particles are not inherently more toxic than larger particles, but the effects are complex and vary based on particle properties as well as chemical toxicity. This Report brings together the latest science on environmental safety considerations specific to manufactured nanoscale materials, and some possible implications for policy and research.

The post Speaker manufacturer produces face shields the hi-fi way appeared first on The Lead SA.

The post Hi-tech armour manufacturer lands first commercial contract appeared first on The Lead SA.

The post Global shutdown could spark Australian manufacturing revival appeared first on The Lead SA.

The post Australian armour manufacturer secures first international order appeared first on The Lead SA.

...

Manufacturing companies will get more help in adopting digital technology with the HP-NTU Digital Manufacturing Corporate Lab officially opened at NTU. The facility, created through a collaboration between NTU and global technology giant HP, showcases digital manufacturing technologies that can make manufacturing and supply chain operations more efficient, cost-effective and sustainable....

Vipp, the venerable purveyor of high-end trash bins, gets into the prefab vacation home business.

The Voynich Manuscript, an illustrated codex from Medieval times, has been baffling humans since 1912. Here's what we know about it.

Fair Oaks Farms now powers 42 tractor-trailers with compressed natural gas from methane, the largest project of its kind to date.

MPCB system, protection from Overload, Phase failure and Short Circuit(J7MC Series)

Imagine if your great, great grandfather or grandmother had left you a book with their secrets for living. Maybe it contained nuggets of wisdom, yummy recipes, favorite jokes, or just insights for how to lead a good life. You can leave such a book for your own family.

Mr. Kaidanov has been endorsed by Marquis Who's Who as a leader in the fencing field

Southern California supplement manufacturer, Ultra Botanicals, bases its business model and newest formulas on what it calls "simple facts," which are: science, studies, bio-chemical makeup and customer feedback.

This is after the launch of WeeTect football visors (WFV) that features superior fog and abrasion resistant besides, being evaluated for CE and ASTM compliance standards.